- Recommendation ID
- NG191/15
- Question
What is the effectiveness and safety of neutralising monoclonal antibodies against different SARS-CoV-2 variants?
- Any explanatory notes
(if applicable) Suggested PICO (Population, Intervention, Comparator, Outcome)
P: people being treated for acute COVID-19 disease and who are not hospitalised with COVID-19
Subgroups of particular interest:
- ethnicity
- children and young people
- pregnant women
- vaccination status
- people with comorbidities
- people who are immunocompromised
I: neutralising monoclonal antibodies
- combination of casirivimab and imdevimab
- sotrovimab
- any neutralising monoclonal antibodies that are granted marketing authorisation in the future
C:
- standard care
- other neutralising monoclonal antibodies
O:
- health-related quality of life
- adverse events
- progression to invasive mechanical ventilation
- progression to non-invasive respiratory support
- hospitalisation and duration of hospitalisation
- mortality
Source guidance details
- Comes from guidance
- COVID-19 rapid guideline: managing COVID-19
- Number
- NG191
- Date issued
- March 2021
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 26/01/2022 |